Stem Cell Discovery Through Diversity Act - Requires the Director of the National Institutes of Health (NIH), acting through the national research institutes, to conduct and support research that uses human embryonic stem cells in accordance with the final guidelines issued by NIH and published in the Federal Register on August 25, 2000, including: (1) the requirements that stem cells used in research be derived from human embryos that were created in vitro for fertility treatments and were in excess of the clinical needs of the individual seeking such treatment and that such individuals voluntarily donated such embryos with informed consent; and (2) the prohibition against the use of Federal funds to derive such cells from the embryos. Provides that restrictions on such research established by the Department of Health and Human Services pursuant to policies announced by the President on August 9, 2001, have no legal effect after enactment of this Act. Prohibits additional Federal administrative policies on such research from being established or applied.
Requires the Director to ensure that such research program include a significant number of donations from individuals who are members of racial or ethnic minority groups in order to make progress toward the goal of developing an understanding of whether the variables studied in clinical research affect such groups differently.
Requires the Director to establish the Ronald Reagan Office of Human Stem Cell Research to coordinate all research conducted or supported by NIH that used human pluripotent stem cells.
[Congressional Bills 108th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4812 Introduced in House (IH)]
108th CONGRESS
2d Session
H. R. 4812
To require the National Institutes of Health to conduct and support
research using human embryonic stem cells, and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
July 12, 2004
Mr. Deutsch introduced the following bill; which was referred to the
Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To require the National Institutes of Health to conduct and support
research using human embryonic stem cells, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Stem Cell Discovery Through
Diversity Act''.
SEC. 2. STEM CELL RESEARCH; REQUIREMENT REGARDING RELATION TO
INFERTILITY TREATMENT; DIVERSITY IN STEM CELLS.
(a) In General.--The Director of the National Institutes of Health
(referred to in this Act as the ``Director of NIH''), acting through
the national research institutes, shall in accordance with this section
conduct and support research using human embryonic stem cells.
(b) Applicability of 2000 NIH Final Guidelines.--
(1) In general.--The Director of NIH shall ensure that
research under subsection (a) is conducted and supported in
accordance with the final guidelines regarding such research
that were issued by the National Institutes of Health and
published in the Federal Register on August 25, 2000 (65 FR
51976 et seq.), including--
(A) the requirement that human embryonic stem cells
used in the research be derived from human embryos that
were created in vitro for purposes of fertility
treatment and were in excess of the clinical need of
the individuals seeking such treatment;
(B) the requirement that individuals seeking such
treatment voluntarily donated such embryos through a
process of informed consent; and
(C) the prohibition that Federal funds may not be
used for the derivation of such cells from the embryos.
(2) Certain restrictions.--Restrictions on research
described in subsection (a) established for the Department of
Health and Human Services pursuant to policies announced by the
President on August 9, 2001, have no legal effect on or after
the date of the enactment of this Act.
(3) Additional administrative polices.--With respect to
research under subsection (a), Federal administrative policies
in addition to the guidelines under paragraph (1) may not be
established or applied.
(c) Diversity in Sources of Stem Cells.--With respect to donations
referred to in subsection (b)(1)(B) (relating to sources of human
embryonic stem cells), the Director of NIH shall ensure that the
program under subsection (a) includes donations from a significant
number of individuals who are members of racial or ethnic minority
groups in order to make progress toward the goal (consistent with
principles underlying the requirement under section 492B of the Public
Health Service Act that such individuals be included as subjects in
research) of developing an understanding of whether the variables
studied in clinical research affect such individuals differently than
the general population.
(d) Report to Congress.--The Director of NIH shall annually submit
to the Congress a report on the program of research carried out under
subsection (a). The report shall include a description of the actions
taken by the Director to comply with subsection (c) and a determination
by the Director of the progress being made toward the goal described in
such subsection.
SEC. 3. RONALD REAGAN OFFICE OF HUMAN STEM CELL RESEARCH.
The Director of NIH shall establish within the office of the
Director an office to be known as the Ronald Reagan Office of Human
Stem Cell Research, which shall be headed by a director appointed by
the Director of NIH. The Office shall coordinate all research conducted
or supported by the National Institutes of Health that uses human
pluripotent stem cells.
<all>
Introduced in House
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line